Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABBV AbbVie	$211.02 +0.1%	$210.78	$180.25 ▼ $244.81	$372.40B	0.32	7.03 million shs	3.14 million shs
ASND Ascendis Pharma A/S	$240.74 -1.9%	$232.19	$153.49 ▼ $250.74	$15.02B	0.41	698,899 shs	320,040 shs
ATHA Athira Pharma	$11.00 +6.6%	$9.02	$0.23 ▼ $8.36	$43.38M	2.79	602,475 shs	85,519 shs
AZN Astrazeneca	$181.54 -1.8%	$192.70	$136.16 ▼ $212.71	$281.76B	0.26	2.67 million shs	1.03 million shs
JNJ Johnson & Johnson	$227.07 -1.6%	$235.49	$149.04 ▼ $251.71	$547.39B	0.27	8.37 million shs	4.33 million shs
JNJ Johnson & Johnson	$227.07 -1.6%	$235.49	$149.04 ▼ $251.71	$547.39B	0.27	8.37 million shs	4.33 million shs

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for May 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABBV AbbVie	+1.23%	+4.13%	+0.32%	-8.90%	+18.98%
ASND Ascendis Pharma A/S	+0.78%	-0.26%	-1.74%	+13.48%	+56.16%
ATHA Athira Pharma	+1.47%	+9.55%	+6.39%	+120.51%	+297.38%
AZN Astrazeneca	-1.49%	+1.22%	-9.52%	-10.04%	+39.59%
JNJ Johnson & Johnson	+0.08%	+3.70%	-3.97%	-5.24%	+57.53%
JNJ Johnson & Johnson	+0.08%	+3.70%	-3.97%	-5.24%	+57.53%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABBV AbbVie	$211.02 +0.1%	$210.78	$180.25 ▼ $244.81	$372.40B	0.32	7.03 million shs	3.14 million shs
ASND Ascendis Pharma A/S	$240.74 -1.9%	$232.19	$153.49 ▼ $250.74	$15.02B	0.41	698,899 shs	320,040 shs
ATHA Athira Pharma	$11.00 +6.6%	$9.02	$0.23 ▼ $8.36	$43.38M	2.79	602,475 shs	85,519 shs
AZN Astrazeneca	$181.54 -1.8%	$192.70	$136.16 ▼ $212.71	$281.76B	0.26	2.67 million shs	1.03 million shs
JNJ Johnson & Johnson	$227.07 -1.6%	$235.49	$149.04 ▼ $251.71	$547.39B	0.27	8.37 million shs	4.33 million shs
JNJ Johnson & Johnson	$227.07 -1.6%	$235.49	$149.04 ▼ $251.71	$547.39B	0.27	8.37 million shs	4.33 million shs

A Guide To High-Short-Interest Stocks

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABBV AbbVie	+1.23%	+4.13%	+0.32%	-8.90%	+18.98%
ASND Ascendis Pharma A/S	+0.78%	-0.26%	-1.74%	+13.48%	+56.16%
ATHA Athira Pharma	+1.47%	+9.55%	+6.39%	+120.51%	+297.38%
AZN Astrazeneca	-1.49%	+1.22%	-9.52%	-10.04%	+39.59%
JNJ Johnson & Johnson	+0.08%	+3.70%	-3.97%	-5.24%	+57.53%
JNJ Johnson & Johnson	+0.08%	+3.70%	-3.97%	-5.24%	+57.53%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABBV AbbVie	2.88	Moderate Buy	$253.43	20.10% Upside
ASND Ascendis Pharma A/S	2.95	Moderate Buy	$291.78	21.20% Upside
ATHA Athira Pharma	1.00	Sell	$4.00	-63.64% Downside
AZN Astrazeneca	2.85	Moderate Buy	$205.33	13.10% Upside
JNJ Johnson & Johnson	2.74	Moderate Buy	$253.04	11.44% Upside
JNJ Johnson & Johnson	2.74	Moderate Buy	$253.04	11.44% Upside

Current Analyst Ratings Breakdown

Latest AZN, ABBV, JNJ, ATHA, ASND, and JNJ Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/15/2026	ASND Ascendis Pharma A/S	Evercore Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$329.00
5/15/2026	ABBV AbbVie	Evercore Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$235.00
5/14/2026	ABBV AbbVie	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$294.00 ➝ $298.00
5/14/2026	AZN Astrazeneca	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
5/13/2026	JNJ Johnson & Johnson	Johnson Rice Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Outperform
5/13/2026	JNJ Johnson & Johnson	Johnson Rice Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Outperform
5/13/2026	AZN Astrazeneca	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
5/13/2026	JNJ Johnson & Johnson	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform	$265.00
5/13/2026	JNJ Johnson & Johnson	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform	$265.00
5/11/2026	ASND Ascendis Pharma A/S	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$342.00 ➝ $345.00
5/8/2026	ASND Ascendis Pharma A/S	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$330.00 ➝ $326.00

(Data available from 5/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABBV AbbVie	$61.16B	6.10	$15.32 per share	13.77	($3.74) per share	-56.42
ASND Ascendis Pharma A/S	$814.57M	18.44	N/A	N/A	$9.16 per share	26.28
ATHA Athira Pharma	N/A	N/A	N/A	N/A	$11.60 per share	N/A
AZN Astrazeneca	$58.74B	4.79	$12.50 per share	14.52	$30.55 per share	5.94
JNJ Johnson & Johnson	$94.19B	5.80	$13.91 per share	16.32	$33.73 per share	6.73
JNJ Johnson & Johnson	$94.19B	5.80	$13.91 per share	16.32	$33.73 per share	6.73

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABBV AbbVie	$4.23B	$2.03	103.83	12.98	0.72	5.79%	-576.45%	13.39%	7/30/2026 (Estimated)
ASND Ascendis Pharma A/S	-$258M	$8.67	27.78	23.46	N/A	57.87%	N/A	-8.37%	N/A
ATHA Athira Pharma	-$96.94M	-$9.68	N/A	N/A	N/A	N/A	-107.06%	-89.89%	N/A
AZN Astrazeneca	$10.23B	$6.66	27.28	15.72	1.54	17.19%	30.86%	12.68%	7/27/2026 (Estimated)
JNJ Johnson & Johnson	$26.80B	$8.65	26.29	18.05	2.26	21.83%	32.60%	13.29%	7/15/2026 (Estimated)
JNJ Johnson & Johnson	$26.80B	$8.65	26.29	18.05	2.26	21.83%	32.60%	13.29%	7/15/2026 (Estimated)

Latest AZN, ABBV, JNJ, ATHA, ASND, and JNJ Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/7/2026	Q1 2026	ASND Ascendis Pharma A/S	$0.21	$0.32	+$0.11	$11.29	$362.47 million	$285.45 million
4/29/2026	Q1 2026	ABBV AbbVie	$2.59	$2.65	+$0.06	$0.39	$14.72 billion	$15.00 billion
4/29/2026	Q1 2026	AZN Astrazeneca	$2.52	$2.58	+$0.06	$0.9850	$14.93 billion	$15.29 billion
4/14/2026	Q1 2026	JNJ Johnson & Johnson	$2.68	$2.70	+$0.02	$2.14	$23.60 billion	$24.06 billion
4/14/2026	Q1 2026	JNJ Johnson & Johnson	$2.68	$2.70	+$0.02	$2.14	$23.60 billion	$24.06 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABBV AbbVie	$6.92	3.28%	+6.80%	340.89%	53 Years
ASND Ascendis Pharma A/S	N/A	N/A	N/A	N/A	N/A
ATHA Athira Pharma	N/A	N/A	N/A	N/A	N/A
AZN Astrazeneca	$4.34	2.39%	+2.30%	65.17%	N/A
JNJ Johnson & Johnson	$5.20	2.29%	+5.25%	60.12%	64 Years
JNJ Johnson & Johnson	$5.20	2.29%	+5.25%	60.12%	64 Years

Latest AZN, ABBV, JNJ, ATHA, ASND, and JNJ Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
4/14/2026	JNJ Johnson & Johnson	quarterly	$1.34	2.23%	5/26/2026	5/26/2026	6/9/2026
4/14/2026	JNJ Johnson & Johnson	quarterly	$1.34	2.23%	5/26/2026	5/26/2026	6/9/2026
2/19/2026	ABBV AbbVie	quarterly	$1.73	3.32%	4/15/2026	4/15/2026	5/15/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABBV AbbVie	N/A	0.80	0.56
ASND Ascendis Pharma A/S	0.79	1.00	0.72
ATHA Athira Pharma	N/A	9.70	9.70
AZN Astrazeneca	0.52	0.91	0.71
JNJ Johnson & Johnson	0.46	1.03	0.77
JNJ Johnson & Johnson	0.46	1.03	0.77

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABBV AbbVie	70.23%
ASND Ascendis Pharma A/S	N/A
ATHA Athira Pharma	57.12%
AZN Astrazeneca	20.35%
JNJ Johnson & Johnson	69.55%
JNJ Johnson & Johnson	69.55%

Insider Ownership

Company	Insider Ownership
ABBV AbbVie	0.06%
ASND Ascendis Pharma A/S	40.00%
ATHA Athira Pharma	19.80%
AZN Astrazeneca	N/A
JNJ Johnson & Johnson	0.16%
JNJ Johnson & Johnson	0.16%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABBV AbbVie	57,000	1.77 billion	1.77 billion	Optionable
ASND Ascendis Pharma A/S	1,189	62.38 million	37.43 million	Optionable
ATHA Athira Pharma	40	3.94 million	3.16 million	No Data
AZN Astrazeneca	96,100	1.55 billion	N/A	N/A
JNJ Johnson & Johnson	138,200	2.41 billion	2.40 billion	Optionable
JNJ Johnson & Johnson	138,200	2.41 billion	2.40 billion	Optionable

AZN, ABBV, JNJ, ATHA, ASND, and JNJ Headlines

Recent News About These Companies

Congressman A Big Fan Of Dividend Reinvestments: Here's His Core Blue Chip Stocks

1 hour ago | benzinga.com

Alto Neuroscience CEO Amit Etkin, M.D., Ph.D. Receives Columbia University Transformational Research Award

3 hours ago | finance.yahoo.com

How Important Are Skyrizi and Rinvoq to AbbVie's Q1 Results?

3 hours ago | finance.yahoo.com

If You Have $480,000 Saved at 67 and Just Sold a Restaurant for $1.1 Million Cash, Here Is the Income Plan That Actually Holds

3 hours ago | 247wallst.com

How Important Are Skyrizi and Rinvoq to AbbVie's Q1 Results?

3 hours ago | zacks.com

TREMFYA Sales Forecast and Market Size Analysis Report 2026-2034 with Focus on United States, Germany, France, Italy, Spain, United Kingdom, and Japan

May 15 at 7:32 AM | finance.yahoo.com

Phoenix Financial Ltd. Acquires 19,874 Shares of Johnson & Johnson $JNJ

May 15 at 6:40 AM | marketbeat.com

Thrivent Financial for Lutherans Lowers Holdings in Johnson & Johnson $JNJ

May 15 at 6:31 AM | marketbeat.com

New York Life Investment Management LLC Buys 11,886 Shares of Johnson & Johnson $JNJ

May 15 at 6:13 AM | marketbeat.com

Mesirow Financial Investment Management Inc. Cuts Stock Holdings in Johnson & Johnson $JNJ

May 15 at 6:04 AM | marketbeat.com

Johnson & Johnson $JNJ Shares Sold by Bessemer Group Inc.

May 15 at 4:22 AM | marketbeat.com

Johnson & Johnson $JNJ Shares Sold by Conning Inc.

May 15 at 4:14 AM | marketbeat.com

Arbejdsmarkedets Tillaegspension Invests $24.07 Million in Johnson & Johnson $JNJ

May 15 at 3:16 AM | marketbeat.com

ACR Alpine Capital Research LLC Grows Stock Position in Johnson & Johnson $JNJ

May 15 at 3:07 AM | marketbeat.com

How The Story For Johnson & Johnson (JNJ) Is Shifting With New Drugs And Legal Twists

May 15 at 1:37 AM | finance.yahoo.com

Groundbreaking global survey captures the significant patient burden experienced with current standard-of-care bladder cancer treatments, underscoring urgency for continued innovation

May 14 at 8:36 PM | finance.yahoo.com

Groundbreaking global survey captures the significant patient burden experienced with current standard-of-care bladder cancer treatments, underscoring urgency for continued innovation

May 14 at 4:01 PM | prnewswire.com

Why Is Johnson & Johnson (JNJ) Down 3.5% Since Last Earnings Report?

May 14 at 12:31 PM | zacks.com

Leerink Partners upgrades Johnson & Johnson (JNJ)

May 14 at 9:14 AM | msn.com

MeiraGTx Reports First Quarter 2026 Financial and Operational Results

May 14 at 9:14 AM | finance.yahoo.com

CAPLYTA Data Highlights Johnson & Johnson Valuation And Mental Health Story

May 14 at 9:14 AM | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

AZN, ABBV, JNJ, ATHA, ASND, and JNJ Company Descriptions

AbbVie NYSE:ABBV

$211.02 +0.25 (+0.12%)

As of 03:54 PM Eastern

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Ascendis Pharma A/S NASDAQ:ASND

$240.74 -4.75 (-1.93%)

As of 03:54 PM Eastern

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

Athira Pharma NASDAQ:ATHA

$11.00 +0.68 (+6.59%)

As of 05/14/2026

Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies. The company's product pipeline includes ATH-1020, an orally available brain-penetrant small molecule designed to enhance the HGF/MET system that is in Phase 1 clinical trials to treat neuropathic pain and neurodegenerative diseases; and ATH-1105, an oral small molecule drug candidate, which is a preclinical model for the treatment of Amyotrophic Lateral Sclerosis. In addition, it has a license agreement with Washington State University to offer for sale products covered by certain licensed patents, including dihexa, the chemical compound into which fosgonimeton metabolizes following administration; and collaboration and grant agreement with National Institutes of Health Grant to support ACT-AD Phase 2 clinical trial for fosgonimeton. The company was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. Athira Pharma, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington.

Astrazeneca NYSE:AZN

$181.54 -3.42 (-1.85%)

As of 03:54 PM Eastern

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Johnson & Johnson NYSE:JNJ

$227.07 -3.73 (-1.61%)

As of 03:54 PM Eastern

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Johnson & Johnson NYSE:JNJ

$227.07 -3.73 (-1.61%)

As of 03:54 PM Eastern

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AZN, ABBV, JNJ, ATHA, ASND, and JNJ Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AZN, ABBV, JNJ, ATHA, ASND, and JNJ Earnings

Compare Dividends

Latest AZN, ABBV, JNJ, ATHA, ASND, and JNJ Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AZN, ABBV, JNJ, ATHA, ASND, and JNJ Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

AZN, ABBV, JNJ, ATHA, ASND, and JNJ Company Descriptions

AbbVie NYSE:ABBV

Ascendis Pharma A/S NASDAQ:ASND

Athira Pharma NASDAQ:ATHA

Astrazeneca NYSE:AZN

Johnson & Johnson NYSE:JNJ

Johnson & Johnson NYSE:JNJ

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools